<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04797819</url>
  </required_header>
  <id_info>
    <org_study_id>sST2 and plaque vulnerability</org_study_id>
    <nct_id>NCT04797819</nct_id>
  </id_info>
  <brief_title>Serum Soluble ST2 and Plaque Vulnerability in Patients With Acute Coronary Syndrome</brief_title>
  <official_title>Elevated Serum Soluble ST2 Level is Associated With Increased Plaque Vulnerability in Patients With Non-ST Elevation Acute Coronary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RenJi Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aimed to assess the association between serum sST2 level and plaque vulnerability&#xD;
      in ACS patients. It is hypothesized that serum sST2 level may be related to plaque components&#xD;
      and closely associated with plaque vulnerability.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Serum soluble suppression of tumorigenicity-2 (sST2) has emerged as a novel biomarker of&#xD;
      atherosclerotic disease. This study aimed to investigate whether elevated serum sST2 level is&#xD;
      related to coronary plaque components detected on coronary computed tomography angiography&#xD;
      (CCTA) and plaque vulnerability in non-ST elevation acute coronary syndromes (ACS) patients.&#xD;
      167 lesions in 120 non-ST elevation ACS patients were prospectively enrolled and evaluated by&#xD;
      CCTA in this study. Blood were taken from antecubital vein during patient's hospitalization&#xD;
      for angiography. Serum sST2 level was measured by commerical ELISA kits (Presage ST2 Assay&#xD;
      Kit, Critical Diagnostics). CCTA were performed using a 320-slice CT scanner (Aquilion ONE,&#xD;
      Toshiba Medical Systems, Otawara, Japan). Coronary plaque components were analyzed cross each&#xD;
      of the lesions using commercialized software package (QAngio CT, Medis, The Netherlands).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Distribution of plaque components by QAngioCT</measure>
    <time_frame>Procedure (Coronary CTA )</time_frame>
    <description>Hounsfield unit (HU) -30 to 75 for necrotic core, HU 76-130 for fibrous fatty, HU 131-350 for fibrous tissue, and HU over 351 for dense calcium.</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">120</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Serum sST2 level &lt; 14.5 ng/mL</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>14.5 ng/mL ≤ Serum sST2 level &lt; 20.5 ng/mL</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>20.5 ng/mL ≤ Serum sST2 level &lt; 25.9 ng/mL</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Serum sST2 level ≥ 25.9 ng/mL</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Coronary plaque components</intervention_name>
    <description>Coronary plaque components were detected by CCTA method</description>
    <arm_group_label>14.5 ng/mL ≤ Serum sST2 level &lt; 20.5 ng/mL</arm_group_label>
    <arm_group_label>20.5 ng/mL ≤ Serum sST2 level &lt; 25.9 ng/mL</arm_group_label>
    <arm_group_label>Serum sST2 level &lt; 14.5 ng/mL</arm_group_label>
    <arm_group_label>Serum sST2 level ≥ 25.9 ng/mL</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Between January 2019 and December 2019, a total of 120 patients with 167 lesions were&#xD;
        included in our study for final analysis.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Clinical diagnosis of non-ST-elevation ACS&#xD;
&#xD;
               1. Non-ST-elevation myocardial infarction&#xD;
&#xD;
               2. Unstable angina&#xD;
&#xD;
          2. Age from 18 to 75 years&#xD;
&#xD;
          3. Underwent CCTA&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients needed an immediate (&lt; 2 h) or early invasive strategy (&lt; 24 h) according to&#xD;
             guidelines:&#xD;
&#xD;
               1. Haemodynamic instability&#xD;
&#xD;
               2. Cardiogenic shock&#xD;
&#xD;
               3. Life-threatening arrhythmias or cardiac arrest&#xD;
&#xD;
               4. Mechanical complication&#xD;
&#xD;
               5. Acute heart failure&#xD;
&#xD;
               6. Dynamic ST or T wave changes&#xD;
&#xD;
               7. GRACE score &gt; 140&#xD;
&#xD;
          2. Patients with previous history of:&#xD;
&#xD;
               1. Coronary artery bypass graft surgery or percutaneous coronary intervention (PCI)&#xD;
&#xD;
               2. Immune system disorder&#xD;
&#xD;
               3. Tumor&#xD;
&#xD;
               4. Acute/chronic infection&#xD;
&#xD;
               5. Statin use within 3 months&#xD;
&#xD;
               6. Atrial fibrillation&#xD;
&#xD;
               7. End-stage renal failure&#xD;
&#xD;
               8. Iodine-containing contrast allergy&#xD;
&#xD;
          3. Patients with no significant (≥ 50%) stenosis on major epicardial vessels after CCTA&#xD;
             performance&#xD;
&#xD;
          4. Patients refused subsequent angiography after CCTA performance&#xD;
&#xD;
          5. Patients with total obstruction on major epicardial vessel&#xD;
&#xD;
          6. Patients with insufficient image quality for QAngioCT analysis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Song Ding</last_name>
    <role>Principal Investigator</role>
    <affiliation>RenJi Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiology, Ren Ji Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 12, 2021</study_first_submitted>
  <study_first_submitted_qc>March 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2021</study_first_posted>
  <last_update_submitted>March 20, 2021</last_update_submitted>
  <last_update_submitted_qc>March 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>soluble ST2</keyword>
  <keyword>plaque vulnerability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

